https://endpoints.news/fda-approves-novartis-itvisma-for-older-patients-with-spinal-muscular-atrophy/
Nov 25, 2025 - FDA approves Novartis' Itvisma, a new SMA gene therapy for patients 2+ years old at $2.59M, expanding treatment options beyond Zolgensma
fdaitvismaolderpatientsspinal